{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:45:22Z","timestamp":1793843122300,"version":"4.6.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Saudi Dental Journal"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.sdentj.2022.01.003","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T13:44:00Z","timestamp":1642599840000},"page":"202-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies"],"prefix":"10.1007","volume":"34","author":[{"given":"Raed","family":"AlRowis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmalik","family":"Aldawood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"AlOtaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam","family":"Alnasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"AlSaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Aljaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair","family":"Natto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.sdentj.2022.01.003_b0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"Advisory task force on bisphosphonate-related osteonecrosis of the jaws, American Association of Oral and Maxillofacial Surgeons: American Associaaton of Oral and Maxillofacial Syrgeons position paper on bisphosphonate-related osteonecrosi of the jaws","volume":"65","author":"Aaoms","year":"2007","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcms.2007.06.008","article-title":"\u201cBis-phossy jaws\u201d\u2013high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw","volume":"36","author":"Abu-Id","year":"2008","journal-title":"J. Craniomaxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0015","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","article-title":"What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review","volume":"45","author":"Aljohani","year":"2017","journal-title":"J. Craniomaxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/JPER.18-0183","article-title":"Association between time since quitting smoking and periodontitis in former smokers in the National Health and Nutrition Examination Surveys (NHANES) 2009 to 2012","volume":"90","author":"Alharthi","year":"2019","journal-title":"J. Periodontol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/13697137.2015.1099092","article-title":"Bisphosphonate drug holidays\u2013when, why and for how long?","volume":"18","author":"Anagnostis","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.sdentj.2022.01.003_b0030","first-page":"336","article-title":"Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates","volume":"12","author":"Bag\u00e1n","year":"2007","journal-title":"Med. Oral. Patol. Oral. Cir. Bucal."},{"key":"10.1016\/j.sdentj.2022.01.003_b0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","article-title":"Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN","volume":"90","author":"Barasch","year":"2011","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.sdentj.2022.01.003_b0040","first-page":"423","article-title":"Osteonecrosis of the jaw in a patient on raloxifene: a case report","volume":"46","author":"Baur","year":"2015","journal-title":"Quintessence. Int."},{"key":"10.1016\/j.sdentj.2022.01.003_b0045","doi-asserted-by":"crossref","first-page":"e13334","DOI":"10.1111\/dth.13334","article-title":"Autologous platelet-rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication-related osteonecrosis of the jaw","volume":"33","author":"Bennardo","year":"2020","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.sdentj.2022.01.003_b0050","doi-asserted-by":"crossref","first-page":"104659","DOI":"10.1016\/j.oraloncology.2020.104659","article-title":"New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws","volume":"106","author":"Bennardo","year":"2020","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/jofs.jofs_46_18","article-title":"Osteomyelitis of the mandible exhibiting features of medication-related osteonecrosis in a patient with history of tocilizumab treatment","volume":"10","author":"Bindakhil","year":"2018","journal-title":"J. Orofacial. Sci."},{"key":"10.1016\/j.sdentj.2022.01.003_b0060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.oooo.2017.07.011","article-title":"AAOM clinical practice statement: subject: the use of serum C-terminal telopeptide cross-link of type 1 collagen (CTX) testing in predicting risk of osteonecrosis of the jaw (ONJ)","volume":"124","author":"Bugueno","year":"2017","journal-title":"Oral. Surg. Oral. Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0065","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.sdentj.2022.01.003_b0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0075","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.sdentj.2022.01.003_b0080","doi-asserted-by":"crossref","unstructured":"Durie, B.G., Katz, M., Crowley, J., 2005. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353, 99\u2013102; discussion 99\u2013102.","DOI":"10.1056\/NEJM200507073530120"},{"key":"10.1016\/j.sdentj.2022.01.003_b0085","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/rheumatology\/kes351","article-title":"Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy","volume":"52","author":"Ebker","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.sdentj.2022.01.003_b0090","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/odi.12764","article-title":"Medication-related osteonecrosis of the jaw: surgical or non-surgical treatment?","volume":"24","author":"Favia","year":"2018","journal-title":"Oral Dis."},{"key":"10.1016\/j.sdentj.2022.01.003_b0095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jormas.2018.04.006","article-title":"Numb chin syndrome: a reflection of malignancy or a harbinger of MRONJ? A multicenter experience","volume":"119","author":"Fortunato","year":"2018","journal-title":"J. Stomatol. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0100","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcms.2020.01.014","article-title":"Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review","volume":"48","author":"Fortunato","year":"2020","journal-title":"J. Craniomaxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","article-title":"Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology","volume":"15","author":"Fusco","year":"2016","journal-title":"Exp. Opin. Drug Saf."},{"key":"10.1016\/j.sdentj.2022.01.003_b0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/j.sdentj.2022.01.003_b0115","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.joms.2017.10.024","article-title":"Can autofluorescence guide surgeons in the treatment of medication-related osteonecrosis of the jaw? A prospective feasibility study","volume":"76","author":"Giudice","year":"2018","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.oooo.2020.04.808","article-title":"Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study","volume":"130","author":"Hallmer","year":"2020","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0125","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00784-012-0873-3","article-title":"Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment\u2014a grossly underestimated risk?","volume":"17","author":"Hansen","year":"2013","journal-title":"Clin. Oral. Invest."},{"key":"10.1016\/j.sdentj.2022.01.003_b0130","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J. Am. Dent. Assoc."},{"key":"10.1016\/j.sdentj.2022.01.003_b0135","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.sdentj.2022.01.003_b0140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.id.0000247855.75691.03","article-title":"Medical contraindications to implant therapy: Part I: Absolute contraindications","volume":"15","author":"Hwang","year":"2006","journal-title":"Implant Dent."},{"key":"10.1016\/j.sdentj.2022.01.003_b0145","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","article-title":"A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","volume":"18","author":"Jadu","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5624\/isd.2017.47.1.45","article-title":"Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates","volume":"47","author":"Jeong","year":"2017","journal-title":"Imag. Sci. Dent."},{"key":"10.1016\/j.sdentj.2022.01.003_b0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jobcr.2012.11.001","article-title":"Dental complications and management of patients on bisphosphonate therapy: a review article","volume":"3","author":"Kalra","year":"2013","journal-title":"J. Oral. Biol. Craniofac. Res."},{"key":"10.1016\/j.sdentj.2022.01.003_b0160","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1210\/jc.2006-2036","article-title":"Possible association between diabetes and bisphosphonate-related jaw osteonecrosis","volume":"92","author":"Khamaisi","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.sdentj.2022.01.003_b0165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.sdentj.2022.01.003_b0170","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3899\/jrheum.100221","article-title":"Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons","volume":"38","author":"Khan","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0175","doi-asserted-by":"crossref","unstructured":"S. Khosla, D. Burr, J. Cauley, D.W. Dempster, P.R. Ebeling, D. Felsenberg, R.F. Gagel, V. Gilsanz, T. Guise, S. Koka, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Wiley Online Library, 2007.","DOI":"10.1359\/jbmr.0707onj"},{"key":"10.1016\/j.sdentj.2022.01.003_b0180","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/j.bjoms.2013.09.008","article-title":"Osteonecrosis of the jaw related to everolimus: a case report","volume":"51","author":"Kim","year":"2013","journal-title":"Brit. J .Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jbmr.2985","article-title":"IL-36 induces bisphosphonate-related osteonecrosis of the jaw-like lesions in mice by inhibiting TGF-\u03b2-mediated collagen expression","volume":"32","author":"Kim","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.sdentj.2022.01.003_b0190","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5125\/jkaoms.2014.40.5.206","article-title":"Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw","volume":"40","author":"Kim","year":"2014","journal-title":"J. Korea. Assoc. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0200","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00784-015-1550-0","article-title":"Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow","volume":"20","author":"Kuroshima","year":"2016","journal-title":"Clin. Oral Invest."},{"key":"10.1016\/j.sdentj.2022.01.003_b0205","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ger.12416","article-title":"Medication-related osteonecrosis of the jaw-like lesions in rodents: a comprehensive systematic review and meta-analysis","volume":"36","author":"Kuroshima","year":"2019","journal-title":"Gerodontology"},{"key":"10.1016\/j.sdentj.2022.01.003_b0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","article-title":"Medication-related osteonecrosis of the jaw: a literature review","volume":"61","author":"Kuroshima","year":"2019","journal-title":"J. Oral Biosci."},{"key":"10.1016\/j.sdentj.2022.01.003_b0215","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.11005\/jbm.2015.22.4.167","article-title":"Position statement: drug holiday in osteoporosis treatment with bisphosphonates in South Korea","volume":"22","author":"Lee","year":"2015","journal-title":"J. Bone Metab."},{"key":"10.1016\/j.sdentj.2022.01.003_b0225","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.joms.2008.09.015","article-title":"Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene","volume":"67","author":"Lehrer","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0230","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.oraloncology.2013.05.012","article-title":"Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes","volume":"49","author":"Lerman","year":"2013","journal-title":"Oral Oncol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0235","doi-asserted-by":"crossref","first-page":"115412","DOI":"10.1016\/j.bone.2020.115412","article-title":"Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis","volume":"137","author":"Lesclous","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.sdentj.2022.01.003_b0240","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: a systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med. Oral Patol. Oral Cir. Bucal."},{"key":"10.1016\/j.sdentj.2022.01.003_b0245","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0250","doi-asserted-by":"crossref","unstructured":"Lombard, T., Neirinckx, V., Rogister, B., Gilon, Y., Wislet, S., 2016. Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem. Cells Int.","DOI":"10.1155\/2016\/8768162"},{"key":"10.1016\/j.sdentj.2022.01.003_b0255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/17843286.2017.1348001","article-title":"Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab","volume":"73","author":"Loyson","year":"2018","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0260","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00774-011-0299-z","article-title":"An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence","volume":"30","author":"Malden","year":"2012","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.sdentj.2022.01.003_b0265","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0270","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0275","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0280","doi-asserted-by":"crossref","unstructured":"McArthur, H., Estilo, C., Huryn, J., Williams, T., Fornier, M., Traina, T., Howard, J., Hudis, C., Dickler, M., 2008. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate-and\/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J. Clin. Oncol. 26, 9588\u20139588.","DOI":"10.1200\/jco.2008.26.15_suppl.9588"},{"key":"10.1016\/j.sdentj.2022.01.003_b0285","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/odi.12708","article-title":"Risk factors for medication-related osteonecrosis of the jaws: a systematic review","volume":"24","author":"McGowan","year":"2018","journal-title":"Oral Dis."},{"key":"10.1016\/j.sdentj.2022.01.003_b0290","first-page":"305","article-title":"Bisphosphonate and medication-related osteonecrosis of the jaw: a review","author":"Mucke","year":"2016","journal-title":"Sem. Musculoskelet Radiol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21815\/JDE.019.162","article-title":"Dental students' knowledge and attitudes about electronic cigarettes: a cross-sectional study at one Saudi University","volume":"84","author":"Natto","year":"2020","journal-title":"J Dent. Educ."},{"key":"10.1016\/j.sdentj.2022.01.003_b0300","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/jcpe.12722","article-title":"Efficacy of collagen matrix seal and collagen sponge on ridge preservation in combination with bone allograft: a randomized controlled clinical trial","volume":"44","author":"Natto","year":"2017","journal-title":"J. Clin. Periodontol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0305","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.4119","article-title":"A drug holiday reduces the frequency and severity of medication-related osteonecrosis of the jaw in a minipig model","volume":"35","author":"Otto","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.sdentj.2022.01.003_b0310","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.joms.2008.10.005","article-title":"Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0315","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0320","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0325","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.sdentj.2022.01.003_b0330","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.ijom.2019.04.014","article-title":"Genetic predisposition for medication-related osteonecrosis of the jaws: a systematic review","volume":"48","author":"Sandro Pereira da Silva","year":"2019","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0340","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1620\/tjem.247.75","article-title":"Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone","volume":"247","author":"Shibahara","year":"2019","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.sdentj.2022.01.003_b0345","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1210\/jc.2015-1794","article-title":"Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer","volume":"100","author":"Sim","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.sdentj.2022.01.003_b0350","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s00520-019-05044-0","article-title":"Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study","volume":"28","author":"Soares","year":"2020","journal-title":"Supp. Care Cancer"},{"key":"10.1016\/j.sdentj.2022.01.003_b0355","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s00520-020-05882-3","article-title":"Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis","volume":"29","author":"Srivastava","year":"2021","journal-title":"Supp. Care Cancer"},{"key":"10.1016\/j.sdentj.2022.01.003_b0360","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.joms.2009.04.051","article-title":"Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients","volume":"67","author":"Thumbigere-Math","year":"2009","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0365","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0370","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ors.12153","article-title":"Osteonecrosis of the mandible in a patient with lung adenocarcinoma undergoing anti-angiogenic therapy with bevacizumab","volume":"9","author":"Tzermpos","year":"2016","journal-title":"Oral Surg."},{"key":"10.1016\/j.sdentj.2022.01.003_b0375","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"26","author":"van Cann","year":"2018","journal-title":"Supp. Care Cancer"},{"key":"10.1016\/j.sdentj.2022.01.003_b0380","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.sdentj.2022.01.003_b0385","doi-asserted-by":"crossref","unstructured":"Xie, J., Wang, X., Proud, C.G., 2016. mTOR Inhibitors in Cancer Therapy, F1000Res, 5.","DOI":"10.12688\/f1000research.9207.1"},{"key":"10.1016\/j.sdentj.2022.01.003_b0390","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","article-title":"Antiresorptives and osteonecrosis of the jaw","volume":"12","author":"Yamashita","year":"2012","journal-title":"J. Evid. Based Dent. Pract."},{"key":"10.1016\/j.sdentj.2022.01.003_b0395","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study","volume":"41","author":"Yamazaki","year":"2012","journal-title":"Int. J. Oral Maxillofac. Surg."}],"container-title":["The Saudi Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1013905222000116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1013905222000116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:28:33Z","timestamp":1736166513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1013905222000116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1013905222000116"],"URL":"https:\/\/doi.org\/10.1016\/j.sdentj.2022.01.003","relation":{},"ISSN":["1013-9052"],"issn-type":[{"value":"1013-9052","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies","name":"articletitle","label":"Article Title"},{"value":"The Saudi Dental Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sdentj.2022.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Production and hosting by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}